Clinical Trial Update: Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine [Phase 3]

View source ↗

Summary

Extension study evaluating long-term safety and tolerability of oral atogepant for episodic migraine has completed phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Atogepant (Atogepant)

Snippet

Sponsor: Allergan | Conditions: Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2022-05-12